Mozaheb Zahra, Khooei Alireza
Mashhad University of Medical Sciences, Mashhad, Iran.
Case Rep Hematol. 2018 Feb 12;2018:9590469. doi: 10.1155/2018/9590469. eCollection 2018.
Acute myelogenous leukemia (AML) accounts for 1.2% of all cancer deaths. Relapse is the major cause of treatment failure in acute myeloid leukemia (AML) patients. AML rarely presents as ocular manifestation in relapse or at presentation. The M4 subtype of AML is most commonly presented with extramedullary involvement. In this report, we presented a young female with AML who was diagnosed and treated for AML about 40 months ago. She did not transplant because she did not have a full-match donor. About 4 months ago, she visited with a red eye and conjunctival infiltration. She was referred to an ophthalmologist for a biopsy, and the pathology report showed the relapse of AML which was treated with systemic chemotherapy. Red eyes with subconjunctival nodules in patients with a history of previous AML should raise the suspicion for recurrent disease that warrants urgent biopsy and systemic treatment. Eye involvement with leukemia is usually responsive to systemic chemotherapy.
急性髓系白血病（AML）占所有癌症死亡人数的1.2%。复发是急性髓系白血病（AML）患者治疗失败的主要原因。AML在复发时或初诊时很少表现为眼部症状。AML的M4亚型最常出现髓外浸润。在本报告中，我们介绍了一名年轻女性AML患者，约40个月前被诊断为AML并接受治疗。由于她没有完全匹配的供体，所以未进行移植。大约4个月前，她因眼红和结膜浸润前来就诊。她被转诊至眼科医生处进行活检，病理报告显示为AML复发，随后接受了全身化疗。既往有AML病史的患者出现眼红伴结膜下结节，应怀疑疾病复发，需要紧急活检和全身治疗。白血病眼部受累通常对全身化疗有反应。
